July 2011- Volume 7, Issue 7

July 2011

In this Issue

Government Watch

Congress has questions for J&J, FDA

Congress has questions for J&J, FDA

Lawmaker says FDA lacks sufficient oversight of the pharma’s Puerto Rican plants

Pay-for-delay in play

Pay-for-delay in play

FTC files brief in Third Circuit urging reversal of pay-for-delay ruling in lower court

Biotech industry waits for shot in the arm

Biotech industry waits for shot in the arm

California, Pennsylvania reps co- sponsor renewal bill for Qualifying Therapeutic Discovery Project

Congress proposes big cuts to FDA budget

Congress proposes big cuts to FDA budget

In an attempt to address what they call America’s “destructive spending pattern,” members of the U.S. House Appropriations Committee have proposed a $285 million cut to the U.S. Food and Drug Administration’s (FDA) 2012 spending bill.

When it pays to tattle

When it pays to tattle

SEC clarifies rules, compensates whistleblowers

Omics & Systems Biology

Quintiles redux

Quintiles redux

Quintiles and Population Genetics Technologies join forces as part of the CRO’s new strategy to help biopharma navigate ‘new health’ landscape

Sequence of events

Sequence of events

Complete Genomics to sequence 250 samples for Erasmus University Medical Center for study of cancer and congenital malformations

Proteomics leaders join forces

Proteomics leaders join forces

Proteomics Innovation Network seeks collaborative solutions to unmet needs in drug discovery, personalized medicine

Where no pharma has gone before

Where no pharma has gone before

AstraZeneca, Heptares hone in on high-value GPCR targets

Changing the game

Changing the game

SAIC-Frederick, Biomatrica launch partnership focused on improving molecular analysis in cancer research

Research & Development

Merck, Roche tackle the A’s and B’s of hepatitis C

Merck, Roche tackle the A’s and B’s of hepatitis C

Strategic agreement to focus on improving awareness, treatments of disease

Filling the gap

Filling the gap

Evotec partners with PsychoGenics Inc. to provide integrated CNS drug discovery solutions

Au naturel

Au naturel

Mississippi researchers form partnership to find natural cancer-fighting drugs

Specifar a special catch for Watson

Specifar a special catch for Watson

Acquisition brings significant European commercial presence

Instruments & Informatics

Showtime at the APOLLO

Showtime at the APOLLO

LabCorp agrees to acquire Clearstone Central Laboratories

Knowledge is power

Knowledge is power

With acquisition of Labtronics, PerkinElmer fortifies knowledge-based, enterprise level solutions in core markets

From enterprise ELN to ‘paper on glass’

From enterprise ELN to ‘paper on glass’

Acquisition of Contur Software expands Accelrys’ portfolio with cost-effective, rapid-deployment electronic lab notebook

Under great strain

Under great strain

OpGen partners with U of Maryland to develop a microbial sequence database

Diagnostics

Proteostasis, Elan in neurodegenerative disease deal

Proteostasis, Elan in neurodegenerative disease deal

Partnership combines Proteostasis Network platform with Elan\'s biology, genetics and neurology disease expertise

IVAX’s first quarter one of mixed results

IVAX’s first quarter one of mixed results

IVAX Diagnostics Inc. reported net revenues of $4.1 million in the first quarter of 2011, down from $4.65 million last year.

Congress has questions for J&J, FDA

Congress has questions for J&J, FDA

Lawmaker says FDA lacks sufficient oversight of the pharma’s Puerto Rican plants

Going for growth

Going for growth

Thermo Fisher's $3.5 billion acquisition of Phadia should position it well in high-growth, high-margin specialty diagnostics market

When chocolate’s not enough

When chocolate’s not enough

Nestlé’s new Health Sciences arm ventures into specialty pharma with purchase of Prometheus

Lab21 targets fungal infections

Lab21 targets fungal infections

Personalized medicine company acquires molecular diagnostics firm Myconostica

The power of three

The power of three

Agendia announces colorectal cancer collaboration with AstraZeneca and the Netherlands Cancer Institute

Special Reports

The promise, the pitfalls and a paradigm shift, PART 1

The promise, the pitfalls and a paradigm shift, PART 1

The complex history of stem cell research yields hope for improved human health, unresolved concerns

The promise, the pitfalls and a paradigm shift, PART 2

The promise, the pitfalls and a paradigm shift, PART 2

The complex history of stem cell research yields hope for improved human health, unresolved concerns

Parts of the whole

Parts of the whole

Just like stem cells, global research efforts with them are many and varied

Global News

Shire PLC acquires Advanced BioHealing for $750M

Shire PLC acquires Advanced BioHealing for $750M

Creation of new strategic platform based on tissue regeneration using cell-based therapies complements Shire\'s existing specialist physician focus and biologics manufacturing capability

A Valeant recovery

A Valeant recovery

Valeant Pharmaceuticals signs $446 million deal to acquire Lithuanian company Sanitas shortly after failed bid to take over Cephalon

Takeda takes on transformation

Takeda takes on transformation

Japanese pharma acquires European footprint with $13.7 billion purchase of Switzerland-based Nycomed

Teva spins the globe again

Teva spins the globe again

In effort to reduce reliance on U.S. markets, Teva cuts another global deal

BioCis Pharma and Lx Therapies merge

BioCis Pharma and Lx Therapies merge

New specialty pharmaceutical company will target inflammatory diseases and cancers

Commentary

Guest Commentary: Developing new treatments for antibiotic-resistant bacteria

Guest Commentary: Developing new treatments for antibiotic-resistant bacteria

There is strong demand for new anti-infectives, but major factors are slowing down their commercialization. There are, however, a variety of promising initiatives, including advances involving non-antibiotic anti-infectives and host defense proteins.

Editor's Focus

Stem cell research: Sorting fact from fiction

Stem cell research: Sorting fact from fiction

For the stem cell research arena, the main source of public confusion and debate centers on the use of cell lines derived from human embryos. While society has yet to reach consensus on the ethical and moral dilemmas presented by hESC research, it’s important to remember that it’s not the only form of stem cell research.
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022